Awaiting congressional approval, the United States-Mexico-Canada Agreement could reduce duplicative regulations while increasing intellectual property protections, among other changes.
Regulatory and Compliance
The New Year offers the chance to review your company’s marketing and sales practices given recent enforcement activity
The Irvine, CA-based company said it was limiting the device to only be available for use under clinical protocol with pre-screened patients that adhere to the current indications.
Bayer has already decided to stop selling the controversial birth control device, but FDA says it will continue to monitor the long-term safety of Essure.
Check-Cap received CE mark for its C-Scan Capsule in January of this year, now the Isfiya, Israel-based company is setting its sights on the U.S. market.
FDA said interim results from sampling studies indicate higher-than-expected contamination rates after reprocessing of duodenoscopes currently on the market.
Olympus agreed to pay $85 million to settle a federal investigation of its that began in 2015. A former executive also pleaded guilty and faces up to a year in prison.
FDA proposed a new rule that, if finalized, could motivate more companies to choose the de novo pathway for new devices that do not have a modern predicate.
The EU regulation may have been around for more than a decade, but there is still a lot for medtech to learn.
From 2015 through 2018, about 20% of 510(k) clearances were based on substantial equivalence to a predicate device that was more than a decade old. Should FDA continue to allow this practice, or should older devices be retired as predicates?
A medical device supplier is recalling certain lots of its temporary bipolar pacing leads that are used in conjunction with a compatible external pulse generator for the temporary pacing and sensing of the heart.
Zimmer Biomet initiated the recall due to the lack of adequate validation and controls to ensure that final products were clean and free from bacteria and chemical residue.